Year: 2020

Company Announcement10. November 2020Announcement No. 24NKT A/S Q3 2020: Improved financial results lead to specification of outlook for NKT. High-voltage order backlog at all-time highNKT CEO Alexander Kara says:– NKT delivered improved financial results in Q3 2020 and therefore we also specify our outlook for the full-year results upwards. We were awarded two large high-voltage projects supporting the green transformation, which lead to an all-time high order backlog of over EUR 3bn at the end of the quarter, providing us with improved production visibility for the coming years. After a challenging 1st half 2020, NKT Photonics recorded positive organic growth, while the business continued to be negatively impacted by the COVID-19 pandemic.Q3 2020 financial highlights:*std. metal prices2020 financial outlookThe financial outlook...

Selskabsmeddelelse 10. november 2020Meddelelse nr. 24NKT A/S 3. kvartal 2020:  Forbedrede finansielle resultater fører til præcisering af forventningerne til NKT. Ordrebogen på højspændingsprojekter var rekordhøjNKT CEO Alexander Kara siger:– NKT leverede forbedrede finansielle resultater i 3. kvartal 2020 og derfor har vi præciseret vores forventninger til helårsresultatet opad. Vi blev også tildelt to store højspændingsprojekter som understøtter den grønne omstilling, og som førte til en rekordhøj ordrebog til en værdi af over EUR 3 mia. ved udgangen af kvartalet. Det giver os et forbedret produktionsoverblik over de kommende år. Efter et udfordrende første halvår 2020 leverede NKT Photonics igen positiv organisk vækst, mens forretningen fortsat var negativt påvirket af COVID-19 pandemien. *std. metalpriserFinansielle forventninger...

NoHo Partners PlcNOHO PARTNERS INTERIM REPORT 1 JANUARY–30 SEPTEMBER 2020Quick recovery of demand and profitability measures generated operating cash flow of MEUR 5.5 – restrictions weaken the outlook for the remainder of the yearNoHo Partners operated in a restricted business environment in July–September 2020. Thanks to its efficient operating model, cost savings and the recovery of demand, the Group was able to generate operating cash flow of MEUR 5.5 in spite of the reduced volume and restore profitability to a good level. Turnover in July–September was 73 per cent of the previous year’s level and the EBIT margin was 5.2%. In July–September, the Group conducted its business according to the basic scenario, in which turnover is approximately 70–85 per cent of the previous year’s level.When the restrictions on restaurants in Finland...

NoHo Partners OyjOSAVUOSIKATSAUS 10.11.2020 klo 8.15NOHO PARTNERS OYJ:N OSAVUOSIKATSAUS 1.1.–30.9.2020Kysyntä elpyi nopeasti ja kannattavuustoimenpiteet tuottivat 5,5 miljoonan euron liiketoiminnan operatiivisen kassavirran – rajoitustoimet heikentävät loppuvuoden näkymiäNoHo Partners operoi heinä–syyskuussa 2020 rajoitetussa toimintaympäristössä. Tehokkaan operatiivisen toimintamallin, kustannussäästöjen ja kysynnän elpymisen myötä yhtiö onnistui tuottamaan vajaasta volyymista huolimatta 5,5 miljoonan euron liiketoiminnan operatiivisen kassavirran ja palauttamaan kannattavuuden hyvälle tasolle. Liikevaihtotaso heinä–syyskuussa oli 73 % viime vuoden vastaavasta jaksosta ja liikevoittomarginaali oli 5,2 %. Yhtiö toteutti heinä–syyskuussa liiketoimintaansa perusskenaarionsa mukaisesti, jossa liikevaihto on noin 70–85 % edellisvuoden tasosta.Ravintolarajoitusten...

Today 10 November 2020, Tryg shares are traded ex-dividend of DKK 5.25.Attachment13_2020 Tryg shares are traded ex_dividend

Tryg-aktier handles i dag 10. november 2020 eksklusive udbytte på 5,25 DKK.Vedhæftet fil13_2020 Tryg_aktier handles eksklusive udbytte

AdCOVID, a Single-dose Intranasal Vaccine for COVID-19 is Designed to Generate a Broad Immune Response Against COVID-19 with the Unique Ability to Promote Nasal Mucosal ImmunityLonza Agreement Builds on Existing Partnerships and Expands Altimmune’s Commercial Readiness in Preparation to Produce the Commercial Vaccine in 2021GAITHERSBURG, Md. and BASEL, Switzerland, Nov. 10, 2020 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it entered into an agreement with Lonza for the manufacturing of AdCOVID™, Altimmune’s next-generation, single-dose intranasal vaccine candidate for COVID-19. Lonza is a leading global biopharmaceutical manufacturing company with facilities in Europe, North America, and South Asia.Alberto Santagostino, SVP, Head of Cell and Gene Technologies...

Pratteln, Switzerland, November 11, 2020 – Santhera Pharmaceuticals (SIX: SANN) announces that Dario Eklund, Chief Executive Officer, and Andrew Smith, Chief Financial Officer, will present at the Jefferies Virtual London Healthcare Conference at 11:10 GMT on November 17, 2020.Executive management will present an overview of Santhera’s strategic focus and latest developments in moving forward with its lead development compound vamorolone for the treatment of Duchenne muscular dystrophy and will host one-to-one meetings.About SantheraSanthera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera has an exclusive license for all indications worldwide to vamorolone,...